In treating brain diseases, such as canine cognitive dysfunction, most currently available potent drugs have weak therapeutic efficacy. One of the causes is the inability of the substance to reach the brain in therapeutic quantities. These pharmaceuticals lacked targeted mechanisms for drug delivery, coming about in an elevated drugs concentration in imperative organs, which driven to drug harmfulness. In recent years, cell-free treatment (conditioned medium) determined from animal and human stem cells have provided new promise for treating brain diseases, as CM can stimulate the regeneration of neurons and prevent the inflammation and apoptotic of neurons caused by pathology or aging. On the other hand, it is well known that Chitosan-Hydrogel (CH) is a polymer derived from natural sources. It has been authorized for use in biomedical use because of its uncommon biodegradability, biocompatibility, and mucoadhesive properties. CH modification has been utilized to generate nanoparticles (NPs) for intranasal and intravenous brain targeting. NPs shown upgraded drug take-up to the brain with decreased side impacts due to their drawn out contact time with the nasal mucosa, surface charge, nano size, and capacity to extend the tight intersections inside the mucosa. Due to the aforementioned distinctive characteristics, developing CHNPs load with Bovine Umbilical Mesenchymal Stem Cell Conditioned Medium is crucial as a new therapeutic strategy for canine cognitive dysfunction.
Key words: Bovine umbilical mesenchymal stem cell, Canine Cognitive Dysfunction, cell-free therapy, chitosan hydrogel nanoparticle, secretome
|
